[go: up one dir, main page]

ATE173544T1 - Parvovirusrezeptoren und verfahren zur ihrer verwendung - Google Patents

Parvovirusrezeptoren und verfahren zur ihrer verwendung

Info

Publication number
ATE173544T1
ATE173544T1 AT94912271T AT94912271T ATE173544T1 AT E173544 T1 ATE173544 T1 AT E173544T1 AT 94912271 T AT94912271 T AT 94912271T AT 94912271 T AT94912271 T AT 94912271T AT E173544 T1 ATE173544 T1 AT E173544T1
Authority
AT
Austria
Prior art keywords
parvovirus
methods
binding
sample
receptor
Prior art date
Application number
AT94912271T
Other languages
English (en)
Inventor
Neal S Young
Kevin E Brown
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE173544T1 publication Critical patent/ATE173544T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14311Parvovirus, e.g. minute virus of mice
    • C12N2750/14322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
AT94912271T 1993-03-22 1994-03-22 Parvovirusrezeptoren und verfahren zur ihrer verwendung ATE173544T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/034,132 US5449608A (en) 1993-03-22 1993-03-22 Parvovirus B19 receptor and parvovirus B19 detection

Publications (1)

Publication Number Publication Date
ATE173544T1 true ATE173544T1 (de) 1998-12-15

Family

ID=21874512

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94912271T ATE173544T1 (de) 1993-03-22 1994-03-22 Parvovirusrezeptoren und verfahren zur ihrer verwendung

Country Status (8)

Country Link
US (1) US5449608A (de)
EP (1) EP0690990B1 (de)
JP (1) JPH08511865A (de)
AT (1) ATE173544T1 (de)
AU (1) AU6449694A (de)
CA (1) CA2158564A1 (de)
DE (1) DE69414700D1 (de)
WO (1) WO1994022014A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2755817B2 (ja) * 1988-11-14 1998-05-25 アメリカ合衆国 パルボウイルスキャプシド
ATE427488T1 (de) * 1995-06-07 2009-04-15 Progenics Pharm Inc Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion
JPH0910000A (ja) * 1995-06-26 1997-01-14 Nippon Sekijiyuujishiya ヒトパルボウイルスの検出方法及びそのための試薬
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US20040086528A1 (en) * 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
US6528098B2 (en) * 1996-10-22 2003-03-04 Advanced Viral Research Corp. Preparation of a therapeutic composition
US5973128A (en) * 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
US6268349B1 (en) * 1997-04-15 2001-07-31 Advanced Viral Research Corp. Method for treating B19 parvovirus infections
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
MXPA03011802A (es) 2001-06-28 2004-04-02 Chiron Corp Ensayo de diagnostico para parvovirus b19.
EP1421095B1 (de) 2001-08-31 2013-10-09 Gen-Probe Incorporated Assay zum nachweis der nukleinsäure des humanen parvovirus b19
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP1799856A4 (de) * 2004-09-10 2009-03-04 Focus Diagnostics Inc Verfahren und zusammensetzungen zum nachweis von erythrovirus-genotypen
US20090305944A1 (en) * 2005-06-03 2009-12-10 Bbm Holdings, Inc Methods for Providing Palliative Care with AVR 118
US8227583B2 (en) 2007-06-14 2012-07-24 The Board Of Regents For Oklahoma State University Vaccines containing canine parvovirus genetic variants
SG182206A1 (en) * 2007-06-14 2012-07-30 Univ Oklahoma State Vaccines containing canine parvovirus genetic variants
WO2009117615A2 (en) 2008-03-20 2009-09-24 Blood Systems, Inc. Novel divergent picornavirus:cosavirus
AU2010217928B2 (en) 2009-02-26 2013-06-06 Gen-Probe Incorporated Assay for detection of human parvovirus nucleic acid
ES2945966T3 (es) 2011-07-15 2023-07-11 Gen Probe Inc Composiciones y procedimiento para detectar ácido nucleico del parvovirus humano y ácido nucleico del virus de la hepatitis A

Also Published As

Publication number Publication date
DE69414700D1 (de) 1998-12-24
US5449608A (en) 1995-09-12
EP0690990B1 (de) 1998-11-18
EP0690990A1 (de) 1996-01-10
CA2158564A1 (en) 1994-09-29
AU6449694A (en) 1994-10-11
JPH08511865A (ja) 1996-12-10
WO1994022014A1 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
ATE173544T1 (de) Parvovirusrezeptoren und verfahren zur ihrer verwendung
ATE377657T1 (de) Serpin-arzneistoffe zur behandlung einer hiv- infektion und verfahren zu deren verwendung
PL374311A1 (en) Methods for purifying protein
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
DE60039752D1 (de) Herstellung tetravalenter antikörper
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE287948T1 (de) Plasmide dna reinigung durch peg-fällung und säulen-chromatographie
ATE153704T1 (de) Anti-t-zell rezeptordeterminanten zur behandlung von autoimmunkrankheiten
ATE186900T1 (de) Verfahren zur aeroben, weitergehenden biologischen reinigung von abwässern
SE8205244L (sv) Medel for avlegsnande av mikroorganismer fran vevnader
BR9916209A (pt) Cadeia de receptor de citocina
DE69509843D1 (de) Apparat zur Behandlung z.B. von Poststücken
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATE254128T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
EP0871457A4 (de) Isolierte stromazellen und methoden zu deren verwendung
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
MXPA02005236A (es) Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
EP0960937A4 (de) Neues semaphorin-gen: semaphorin y
ATE175212T1 (de) Cai-resistenzproteine kodierende dna, und ihre verwendung
DE69621915D1 (de) Anti-dns-antikörpernachweis mittels erkennung und bindung telomerischer dns-sequenzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties